US 12,404,244 B2
Pan-KIT kinase inhibitor having quinoline structure and application thereof
Jing Liu, Anhui (CN); Qingsong Liu, Anhui (CN); Yun Wu, Anhui (CN); Beilei Wang, Anhui (CN); ZiPing Q, Anhui (CN); Fengming Zou, Anhui (CN); Qingwang Liu, Anhui (CN); Wenchao Wang, Anhui (CN); Cheng Chen, Anhui (CN); Junjie Wang, Anhui (CN); and Li Wang, Anhui (CN)
Assigned to Tarapeutics Science Inc., Anhui (CN)
Appl. No. 17/312,667
Filed by Tarapeutics Science Inc., Anhui (CN)
PCT Filed Dec. 20, 2018, PCT No. PCT/CN2018/122307
§ 371(c)(1), (2) Date Jun. 10, 2021,
PCT Pub. No. WO2020/118753, PCT Pub. Date Jun. 18, 2020.
Claims priority of application No. 201811520008.5 (CN), filed on Dec. 12, 2018.
Prior Publication US 2022/0064117 A1, Mar. 3, 2022
Int. Cl. C07D 215/22 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61P 35/00 (2006.01); C07D 405/12 (2006.01)
CPC C07D 215/22 (2013.01) [A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61P 35/00 (2018.01); C07D 405/12 (2013.01)] 8 Claims
 
1. A kinase inhibitor, comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, ester, or acid thereof, wherein the compound inhibits activity of wild-type KIT and/or mutant KIT kinase:

OG Complex Work Unit Chemistry
wherein Y is

OG Complex Work Unit Chemistry
A is phenyl;
n is 1;
R1 is selected from hydrogen, halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy and cyano;
each of R2 and R3 is independently selected from hydrogen, halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, or R2 and R3 together form a phenyl or 5-membered heterocyclyl.